Skip to main content
MACROGENICS INC logo

MACROGENICS INC — Investor Relations & Filings

Ticker · MGNX ISIN · US5560991094 LEI · 5493001KJQUA83L8MH79 US Manufacturing
Open in API
Filings indexed 894 across all filing types
Latest filing 2018-05-07 Interim / Quarterly Rep…
Country US United States of America
Listing US MGNX

About MACROGENICS INC

https://www.macrogenics.com/

MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative antibody-based therapeutics for the treatment of cancer. The company utilizes its proprietary antibody engineering platforms, including the DART (Dual-Affinity Re-Targeting) and TRIDENT technologies, to create novel product candidates. Its pipeline consists of investigational treatments such as monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific antibodies. MacroGenics maintains fully-integrated capabilities, from research and discovery through to GMP (Good Manufacturing Practice) manufacturing, to advance its portfolio of potential medicines for patients with unmet medical needs.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q1 2018
2018-05-07 English
DEFINITIVE PROXY STATEMENT
Proxy Solicitation & Information Statement
2018-04-06 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes an underwriting agreement for a stock offering, including details about the number of shares, price, underwriters, and closing date. It also references exhibits such as the underwriting agreement and legal opinion. This is a typical capital/financing update announcing a new equity offering and related agreements. The document is not a full financial report, earnings release, or management discussion, but rather a specific event disclosure related to financing. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2018-04-02 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus supplement and accompanying prospectus for a public offering of common stock by MacroGenics, Inc. It includes registration fee calculations, underwriting details, risk factors, use of proceeds, and other offering-related information. The document is filed pursuant to Rule 424(b)(5), which is a prospectus supplement filing under the Securities Act of 1933. This type of document is related to capital raising activities and financing updates rather than a financial report, earnings release, or management discussion. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a report publication announcement but a substantive filing about a financing event.
2018-03-28 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a preliminary prospectus supplement filed pursuant to Rule 424(b)(5) with the SEC, related to an offering of common stock by MacroGenics, Inc. It includes detailed information about the offering, underwriting, risk factors, use of proceeds, and other related disclosures typical of a securities offering document. The presence of terms like 'preliminary prospectus supplement', 'registration statement', 'offering of common stock', and underwriting details clearly indicate this is a capital raising document. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document is lengthy (15,000 characters) and contains substantive information about the offering, not just an announcement or a brief notice, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). Therefore, the correct classification is CAP with high confidence.
2018-03-26 English
S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by MacroGenics, Inc. It registers additional shares under the company's 2013 Equity Incentive Plan. The text includes details about the registration, signatures of officers, and references to previously filed registration statements. It is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration. Therefore, it fits best under Regulatory Filings (RNS). The document length and content confirm it is not a brief announcement or a report publication notice.
2018-03-15 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.